Home › Research › Risk factors
Regional disparities of antidementia drug treatment in Germany: what can we learn for the new generation of Alzheimer’s therapies
Moritz Platen, Eva Gläser, Volker Dahling, Daniela Gesell, Michael Hauptmann, Dirk Horenkamp‐Sonntag, Daniela Koller, Denise Kubat et al.. Alzheimer s Research & Therapy, 2025-12-04
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Overall, 64% of PlwAD received at least one AD-Rx. Rural residency was associated with slightly lower odds of receiving AD-Rx compared to urban areas (OR 0.92; 95%CI 0.87-0.98; p = 0.010), whereas deprivation was not. Interaction models demonstrated that an increased deprivation further reduced AD-Rx odds in rural areas (OR per GISD unit = 0.98; 95% CI 0.96-0.99; p = 0.024). Global Moran's I revealed no significant large-scale clustering (I = 0.011; p = 0.613), but regional analysis identified several regional hotspots (high-high clusters) predominantly in moderately deprived urban areas and coldspots (low-low clusters) in highly deprived or rural areas. Alzheimer's patients in rural and high-deprivation regions face limited access to recommended antidementia medications. Targeted interventions, such as teleconsultations, expanding specialist outreach, and collaborative care models in underserved areas, as well as regional dementia networks and national registries, could promote the equitable delivery of current and future Alzheimer's antibody therapies. However, further qualitative and quantitative research is needed to identify the underlying regional causes of these treatment disparities. TRIAL REGISTRATION: DRKS00031944.
What this study adds
Evidence grade: Low
The record lists 576 participants. This study found that people with Alzheimer's disease in rural and high-deprivation regions of Germany had lower odds of receiving antidementia medications. Reported effect size: OR 0.92.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Platen, M., Gläser, E., Dahling, V., Gesell, D., Hauptmann, M., Horenkamp‐Sonntag, D., et al. (2025). Regional disparities of antidementia drug treatment in Germany: what can we learn for the new generation of Alzheimer’s therapies. Alzheimer s Research & Therapy. https://doi.org/10.1186/s13195-025-01902-8
Vancouver
Platen M, Gläser E, Dahling V, Gesell D, Hauptmann M, Horenkamp‐Sonntag D, et al. Regional disparities of antidementia drug treatment in Germany: what can we learn for the new generation of Alzheimer’s therapies. Alzheimer s Research & Therapy. 2025. doi:10.1186/s13195-025-01902-8. PMID: 41345718.
BibTeX
@article{platen2025-41345718,
author = {Platen, Moritz and Gläser, Eva and Dahling, Volker and Gesell, Daniela and Hauptmann, Michael and Horenkamp‐Sonntag, Dirk and Koller, Daniela and Kubat, Denise and others},
title = {{Regional disparities of antidementia drug treatment in Germany: what can we learn for the new generation of Alzheimer’s therapies}},
journal = {Alzheimer s Research \& Therapy},
year = {2025},
doi = {10.1186/s13195-025-01902-8},
pmid = {41345718},
url = {https://doi.org/10.1186/s13195-025-01902-8}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Overall, 64% of PlwAD received at least one AD-Rx.
- Rural residency was associated with slightly lower odds of receiving AD-Rx compared to urban areas (OR 0.92; 95%CI 0.87-0.98; p = 0.010), whereas deprivation was not.
- Interaction models demonstrated that an increased deprivation further reduced AD-Rx odds in rural areas (OR per GISD unit = 0.98; 95% CI 0.96-0.99; p = 0.024).
- Global Moran's I revealed no significant large-scale clustering (I = 0.011; p = 0.613), but regional analysis identified several regional hotspots (high-high clusters) predominantly in moderately deprived urban areas and coldspots (low-low clusters) in highly deprived or rural areas.
- Alzheimer's patients in rural and high-deprivation regions face limited access to recommended antidementia medications.
Why it matters
This study found that people with Alzheimer's disease in rural and high-deprivation regions of Germany had lower odds of receiving antidementia medications. It is about access to existing drugs, not about developing or testing a treatment, cure or prevention.
New to this subject? Start with our plain-English guide: Risk factors, ranked →
Study details
- Participants576
- Effect sizeOR 0.92
- Evidence strengthLow
How this study scored 44/100
Published in a peer-reviewed journal. Scored zero for study design and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s Research & Therapy) |
| Journal's citation record | 1 / 4 | Alzheimer s Research & Therapy: journal h-index 146 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 576 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 2 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 1.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Bernhard Michalowsky: h-index 31 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | McMaster University: institution h-index 1,334 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 10 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41345718) |
| Free to read | 2 / 2 | Free to read |
| Total | 44 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1186/s13195-025-01902-8
- PubMed: 41345718
- Original source →
- Free full text: Alzheimer s Research & Therapy →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Risk factors from nearby years
Also in Risk factors
389 studies in the library are filed under Risk factors with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Risk factors hub.